Verona Pharma
Stock Forecast, Prediction & Price Target
Verona Pharma (VRNA) stock Price Target by analysts
$42
Potential downside: -60.12%
Verona Pharma price prediction
What is Verona Pharma stock analysts` prediction?
Verona Pharma stock forecast: Based on 1 Wall Street analysts` predicted price targets for Verona Pharma in the last 3 months, the avarage price target is $42, with a high forecast of $NaN. The average price target represents a -60.12% change from the last price of $105.32.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Verona Pharma stock Price Target by analysts
Full breakdown of analysts given Verona Pharma price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Raghuram Selvaraju H.C. Wainwright | 0% 0/2 | 11 months ago | $42 -60.12% downside | $38.39 | StreetInsider | Previous targets (1) |
Edward Nash Canaccord Genuity | 0% 0/1 | about 1 year ago | $37 -64.86% downside | $22.95 | StreetInsider | Previous targets (0) |
Raghuram Selvaraju H.C. Wainwright | 0% 0/2 | over 1 year ago | $36 -65.81% downside | $14.69 | TheFly | Previous targets (1) |
Andrew Tsai Jefferies | 0% 0/1 | over 1 year ago | $38 -63.91% downside | $12.5 | TheFly | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/1 | over 1 year ago | $36 -65.81% downside | $15.8 | StreetInsider | Previous targets (0) |
Unknown H.C. Wainwright | N/A | almost 3 years ago | $32 -69.61% downside | $18.59 | Benzinga | N/A |
Unknown BTIG | N/A | almost 3 years ago | $26 -75.31% downside | $18.15 | Benzinga | N/A |
Andreas Argyrides Wedbush | 0% 0/1 | almost 3 years ago | $30 -71.51% downside | $18.05 | TheFly | Previous targets (0) |
Unknown Truist Financial | N/A | almost 3 years ago | $28 -73.41% downside | $18.13 | Benzinga | N/A |
Edward Nash Nash Canaccord Genuity | 0% 0/1 | about 3 years ago | $27 -74.36% downside | $10.25 | Pulse 2.0 | Previous targets (0) |
Joon Lee Truist Financial | 100% 1/1 | over 3 years ago | $18 -82.90% downside | $3.85 | Investing | Previous targets (0) |
Verona Pharma Financial Estimates
Verona Pharma Revenue Estimates
Verona Pharma EBITDA Estimates
Verona Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $40M N/A | $458K -98.85% | $0 -100% | Avg: $75.72M Low: $30.32M High: $139.84M avg. 0% | Avg: $230.52M Low: $89.62M High: $431.10M avg. 204.43% | Avg: $580.93M Low: $225.85M High: $1.08B avg. 152.00% | Avg: $1.17B Low: $458.46M High: $2.20B avg. 102.99% |
Net Income
% change YoY
| $-55.56M N/A | $-68.70M -23.63% | $-54.36M 20.86% | Avg: $-72.60M Low: $-104.19M High: $-4.42M avg. -33.53% | Avg: $43.06M Low: $-39.15M High: $22.73M avg. 159.31% | Avg: $64.66M Low: $13.28M High: $137.81M avg. 50.17% | Avg: $159.01M Low: $32.66M High: $338.87M avg. 145.89% |
EBITDA
% change YoY
| $-57.04M N/A | $-62.65M -9.85% | $-52.46M 16.26% | Avg: $-15.14M Low: $-27.96M High: $-6.06M avg. 71.13% | Avg: $-46.10M Low: $-86.22M High: $-17.92M avg. -204.43% | Avg: $-116.18M Low: $-217.27M High: $-45.17M avg. -152.00% | Avg: $-235.85M Low: $-441.06M High: $-91.69M avg. -102.99% |
EPS
% change YoY
| -$0.94 N/A | -$1.04 -10.63% | -$0.54 48.07% | Avg: -$0.37 Low: -$1.31 High: -$0.06 avg. 30.66% | Avg: -$0.07 Low: -$0.49 High: $0.29 avg. 82.44% | Avg: $0.82 Low: $0.17 High: $1.74 avg. 1341.27% | Avg: $2.01 Low: $0.41 High: $4.28 avg. 145.89% |
Operating Expenses
% change YoY
| $97.68M N/A | $66.22M -32.20% | $67.15M 1.39% | Avg: $58.86B Low: $23.57B High: $108.70B avg. 87559.06% | Avg: $179.20B Low: $69.66B High: $335.11B avg. 204.43% | Avg: $451.58B Low: $175.56B High: $844.50B avg. 152.00% | Avg: $916.69B Low: $356.38B High: $1.71T avg. 102.99% |
FAQ
What is Verona Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 80.45% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -104.19M, average is -72.60M and high is -4.42M.
What is Verona Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 114.85% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $30.32M, average is $75.72M and high is $139.84M.
What is Verona Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 400.06% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$1.31, average is -$0.37 and high is $-0.05.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Verona Pharma stock. The most successful analyst is Raghuram Selvaraju.